Immunotherapy
Scope & Guideline
Advancing the Future of Immune-Based Therapies
Introduction
Aims and Scopes
- Cancer Immunotherapy:
The journal extensively covers the latest advancements in cancer immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapy, and combination therapies. It aims to inform clinicians and researchers about the evolving landscape of cancer treatment through immunological approaches. - Primary Immunodeficiency Treatments:
Research on immunoglobulin therapies and novel treatment strategies for primary immunodeficiency diseases is a core focus. The journal seeks to enhance the understanding of pharmacokinetics and dosing strategies to improve patient outcomes. - Adverse Effects and Toxicity Management:
Papers addressing the safety profiles and management of adverse effects related to immunotherapy are frequently published. The journal aims to provide insights into the identification, management, and mitigation of immune-related adverse events. - Emerging Biomarkers and Predictive Models:
The journal emphasizes the identification and validation of biomarkers that predict responses to immunotherapy. This includes studies on tumor microenvironments and immune cell signatures that could guide treatment decisions. - Innovative Therapeutic Strategies:
The journal explores novel therapeutic approaches, such as engineered T cells, bispecific antibodies, and the integration of immunotherapy with other treatment modalities like chemotherapy and targeted therapies.
Trending and Emerging
- Combination Therapies:
There is a growing emphasis on studies that explore the efficacy of combining immunotherapy with other treatment modalities, such as chemotherapy, targeted therapies, or radiation. This trend underscores the move towards more integrative treatment approaches. - Personalized and Precision Medicine:
Research focusing on personalized immunotherapy, including the use of biomarkers to tailor treatments to individual patient profiles, is increasingly prevalent. This reflects a broader trend in medicine towards individualized treatment strategies. - Management of Immune-Related Adverse Events:
As immunotherapy becomes more widely adopted, there is a rising interest in understanding and managing the spectrum of immune-related adverse events. Research addressing these challenges is becoming a critical area of focus. - Innovations in CAR-T and T-cell Therapies:
The development and optimization of CAR-T cell therapies and other engineered T-cell approaches are emerging as significant themes, reflecting advancements in cellular immunotherapy. - Real-World Evidence and Outcomes:
There is an increasing trend towards studies that analyze real-world data to assess the effectiveness and safety of immunotherapy in diverse patient populations, moving beyond clinical trial settings.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decrease in papers focusing solely on traditional chemotherapy methods, as the field increasingly shifts towards combination therapies that integrate immunotherapy with chemotherapy. - Basic Immunology Studies:
Research papers that delve into fundamental immunology without direct clinical applications seem to be diminishing. The journal is increasingly prioritizing clinical and translational studies that have immediate implications for patient care. - Non-Cancer Related Immunotherapy:
The frequency of articles discussing immunotherapy applications outside cancer treatment, such as in autoimmune diseases or infectious diseases, appears to be waning, possibly due to a heightened focus on oncology-related immunotherapy.
Similar Journals
Seminars in Immunopathology
Fostering Collaboration in Immunopathological StudiesSeminars in Immunopathology is a premier academic journal published by SPRINGER HEIDELBERG, focusing on the intricate relationships between immune responses and pathologies. With an ISSN of 1863-2297 and an E-ISSN of 1863-2300, this journal delivers cutting-edge research and insights to its readers, contributing significantly to the fields of immunology and allergy, as reflected in its Q1 quartile ranking in both categories for 2023. Positioned in a highly competitive niche, it ranks #18 out of 233 in Immunology and Allergy and #22 out of 236 in Immunology and Microbiology, highlighting its impact within the scientific community. Seminars in Immunopathology publishes comprehensive reviews and research articles, aiming to advance understanding of immune mechanisms in disease and promote interdisciplinary collaboration. Accessible from Germany, this journal is a vital resource for researchers, clinicians, and students seeking to stay at the forefront of immunological advancements and therapeutic innovations.
Cancer Immunology Research
Fostering Innovation in Cancer ImmunotherapyCancer Immunology Research is a leading journal dedicated to the rapidly evolving field of cancer immunology, published by the American Association for Cancer Research. Established in 2013, this prestigious journal has quickly made a significant impact in its domain, achieving a 2023 Q1 ranking in both Cancer Research and Immunology. With an impressive Scopus rank of 24 out of 230 in cancer research and 28 out of 236 in immunology, it occupies a valuable position for researchers, professionals, and students engaged in cutting-edge cancer studies. Although it does not offer open access, the journal is committed to disseminating high-quality, peer-reviewed research that advances our understanding of the immune system’s role in cancer. The journal's objectives include fostering innovative studies, enhancing collaboration across disciplines, and promoting the translation of research findings into clinical applications, making it a vital resource for anyone invested in cancer therapy and immunological research.
IMMUNOLOGIC RESEARCH
Illuminating Immune Responses for Better Health OutcomesIMUNOLOGIC RESEARCH, published by Springer, is a prestigious journal dedicated to advancing the field of immunology. Since its inception in 1986, this journal has provided a vital platform for researchers, practitioners, and students to share groundbreaking studies and innovative findings that influence clinical and laboratory practices in immunology. With an impact factor that reflects its importance, being ranked in the Q2 category for the year 2023 and positioned at 98th out of 236 in Scopus rankings for Immunology, it is recognized among its peers for the quality of its publications. The journal emphasizes rigorous peer review and encourages submissions across a diverse range of topics including but not limited to immune responses, vaccine development, and disease mechanisms. Though it does not currently offer open access, its insightful articles remain crucial for professionals seeking to stay at the forefront of immunological research. Designed for a broad audience within the scientific community, IMMUNOLOGIC RESEARCH continues to foster discovery and discussion that shapes our understanding of immune function and its implications for health and disease.
Cancer Biology & Medicine
Driving Innovation in Oncology StudiesCancer Biology & Medicine is a distinguished Open Access journal published by the China Anti-Cancer Association, dedicated to advancing research and understanding in the fields of Cancer Research and Oncology. Since its inception in 2012, the journal has provided a vital platform for the dissemination of high-quality research, evidenced by its impressive ranking within the Q1 and Q2 categories of oncology and cancer research as of 2023. With a significant impact factor and a Scopus ranking of #64 in Medicine/Oncology and #55 in Biochemistry, Genetics, and Molecular Biology, it plays a crucial role in shaping the future of cancer biology. By offering open access to its content, the journal ensures that pivotal research findings are readily available to researchers, professionals, and students globally, thereby fostering collaboration and innovation in cancer research. Situated in Tianjin, China, this journal is poised at the frontier of oncology research, making a significant impact through its rigorous peer-reviewed articles that address critical challenges in the field.
CANCER CELL
Empowering the Fight Against CancerCancer Cell, published by Cell Press, represents a pinnacle of research in the fields of cancer research, cell biology, and oncology. With an impressive Impact Factor and ranking as Q1 in prestigious categories for both 2023 and previous years, this journal stands out as a vital resource for professionals and scholars dedicated to understanding the molecular underpinnings of cancer. Operating from Cambridge, MA, Cancer Cell has been an essential platform for innovative studies since its inception in 2002. Although it is not an Open Access journal, its rigorous peer-review process ensures that only the highest quality research is disseminated to the scientific community. Readers can expect to find a wealth of knowledge ranging from cutting-edge therapies to insights into tumor biology, thereby contributing significantly to the advancement of oncology. With rankings placing it among the top echelons of related fields—#2 in Cancer Research and #6 in Oncology—Cancer Cell is an indispensable reference for anyone committed to the fight against cancer.
Journal of the National Cancer Center
Elevating the Standard of Cancer Research and Treatment.Journal of the National Cancer Center, published by Elsevier, serves as a pivotal platform in the fields of Cancer Research, Hematology, and Oncology. With an ISSN of 2667-0054, this esteemed journal is recognized for its exceptional quality, achieving a Q1 ranking in all categories as of 2023. Its impressive Scopus rankings place it among the top journals in its field, notably holding rank #11 in Medicine - Hematology and rank #36 in Medicine - Oncology. Addressed from Amsterdam, Netherlands, the journal aims to disseminate cutting-edge research and innovative findings that advance the understanding and treatment of cancer, bridging gaps between laboratory discoveries and clinical applications. Although it follows a subscription model, the journal's commitment to accessibility ensures that valuable knowledge reaches healthcare professionals and researchers globally. By fostering collaboration and facilitating knowledge exchange, the Journal of the National Cancer Center is indispensable for those dedicated to combating cancer and enhancing patient care.
International Cancer Conference Journal
Leading the Charge Against Cancer Through KnowledgeInternational Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.
Immune Network
Connecting Ideas, Transforming ImmunologyImmune Network is a prestigious journal dedicated to disseminating high-quality research in the field of immunology, infectious diseases, and allergy, under the esteemed KOREA ASSOCIATION OF IMMUNOLOGISTS. Founded in 2016, this journal has quickly ascended to a top-tier publication, achieving Q1 rankings in 2023 in multiple relevant categories, including Immunology, Allergy, and Infectious Diseases. With a strong emphasis on innovation and interdisciplinary research, Immune Network appeals to a diverse audience of researchers, professionals, and students keen on advancing the understanding of immune responses and disease mechanisms. However, it is crucial to note that the journal operates under a subscription model without open-access provisions. Its impact factor further solidifies its reputation, reflecting the significant influence of the articles published. Located in South Korea, the journal serves as a global platform for sharing revolutionary insights and fostering collaborations within the immunology community.
OncoImmunology
Elevating Knowledge in OncoImmunology for Better HealthOncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.
JOURNAL OF GENE MEDICINE
Bridging Laboratory Discoveries with Clinical ApplicationsThe Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.